SCHOTT Pharma AG & Co. KGaA

As of June 30, 2026, SCHOTT Pharma AG & Co. KGaA carries a market capitalization of 2.62B, placing it among publicly traded companies globally. Its enterprise value stands at 2.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

SCHOTT Pharma AG & Co. KGaA's next confirmed earnings release is scheduled for December 10, 2026.

As of June 30, 2026, SCHOTT Pharma AG & Co. KGaA has 150.61M shares outstanding.

As of June 30, 2026, SCHOTT Pharma AG & Co. KGaA trades at a trailing price-to-earnings ratio of 19.04. The price-to-sales ratio is 2.56, and the price-to-book ratio stands at 2.63.

As of June 30, 2026, SCHOTT Pharma AG & Co. KGaA trades at an EV/EBITDA multiple of 9.46 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.54 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.95 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. SCHOTT Pharma AG & Co. KGaA trades at an EV/FCF ratio of 37.59, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 2.58B versus a market cap of 2.62B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, SCHOTT Pharma AG & Co. KGaA maintains a current ratio of 1.61, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, SCHOTT Pharma AG & Co. KGaA posted a return on equity (ROE) of 14.69, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 15.24 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.48, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.06, useful for judging operating efficiency across full business cycles. The company generates approximately 211,475.99 in revenue per employee across its workforce of 4,811.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.13 indicates how many times SCHOTT Pharma AG & Co. KGaA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, SCHOTT Pharma AG & Co. KGaA recorded 38.27M in income tax expense. That works out to an effective tax rate of 21.83, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 175.35M, leaving 136.58M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 6, 2026, SCHOTT Pharma AG & Co. KGaA's stock has gained approximately 16.90% over the past 52 weeks. The 50-day moving average sits at 23.11, while the 200-day moving average is 17.69.

Over the twelve months ended June 30, 2026, SCHOTT Pharma AG & Co. KGaA generated 1.02B in revenue and converted that into 136.58M in net income, yielding earnings per share of 0.92. EBITDA reached 272.61M, while operating income came in at 168.87M.

These figures are as of June 30, 2026. Total book value stands at 996.15M, with working capital of 272.36M providing operational flexibility.

SCHOTT Pharma AG & Co. KGaA produced 193.06M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -137.98M in capital expenditures, free cash flow totaled 55.08M - equivalent to 0.37 per share.

Over the twelve months ended June 30, 2026, SCHOTT Pharma AG & Co. KGaA posted a gross margin of 31.19, reflecting its pricing power and cost economics. The operating margin of 16.60 and net profit margin of 13.42 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, SCHOTT Pharma AG & Co. KGaA paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 2.12, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.80, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to SCHOTT Pharma AG & Co. KGaA shareholders.